Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma

JAMA

Volumn 289, Issue 11, 2003, Pages 1421-1424

  Li, Christopher I ^a   Anderson, Benjamin O ^a,b   Daling, Janet R ^a   Moe, Roger E ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; UNITED STATES; BREAST TUMOR; ESTROGEN THERAPY; INCIDENCE; LUNG CARCINOMA; MIDDLE AGED; PAGET NIPPLE DISEASE; RISK; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RISK; SEER PROGRAM; UNITED STATES;

EID: 0037454283     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.11.1421     Document Type: Article

References (28)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000;88:2570-2577.
4. Newcomer LM, Newcomb PA, Daling JR, Yasui Y, Potter JD. Post-menopausal hormone use and risk of breast cancer by histologic type [abstract]. Am J Epidemiol. 1999;149:S79.
5. Chen CL, Weiss NS, Newcomb P, Badow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-741.
6. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Post-menopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:593-600.
7. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 2002;95:2455-2464.
8. Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol. 1985;65:441-446.
9. Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health. 1988;78:1479-1481.
10. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 1995;85:6-10.
11. Carr BR. HRT management: the American experience. Eur J Obstet Gynecol Reprod Biol. 1996;64 (suppl):S17-S20.
12. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol. 1997;145:536-545.
13. Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tuchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: correlation of histopathology and prognostic factors. Ann Surg. 1993;218:13-21.
14. Du Toit RS, Locker AP, Ellis IO, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol. 1991;17:251-257.
15. Dixon J, Anderson T, Page D, Lee D, Duffy S. Infiltrating lobular carcinoma of the breast. Histopathology. 1982;6:149-161.
16. Yeatman TJ, Cantor AB, Smith TJ, et al. Tumor biology of infiltrating lobular carcinoma: implications for management. Ann Surg. 1995;222:549-559.
17. Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? Cancer. 1994;73:1673-1677.
18. Davis RP, Nora PF, Kooy RG, Hines JR. Experience with lobular carcinoma of the breast: emphasis on recent aspects of management. Arch Surg. 1979;114:485-488.
19. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88:2561-2569.
20. National Cancer Institute. About SEER. Available at: http://seer.cancer.gov/about/. Accessibility verified February 10, 2003.
21. National Cancer Institute. SEER Data Quality. Available at: http://seer.cancer.gov/about/quality.html. Accessibility verified February 10, 2003.
22. National Cancer Institute. Characteristics of the SEER Population Compared with the Total United States Population. Available at: http://www.seer.cancer.gov/registries/characteristics.html. Accessibility verified February 10, 2003.
23. Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull. 1995;118:392-404.
24. Skaane P, Skjorten F. Ultrasonographic evaluation of invasive lobular carcinoma. Acta Radiol. 1999;40:369-375.
25. Evans N, Lyons K. The use of ultrasound in the diagnosis of invasive lobular carcinoma of the breast less than 10 mm in size. Clin Radiol. 2000;55:261-263.
26. Weinstein SP, Orel SG, Heller R, et al. MR imaging of the breast in patients with invasive lobular carcinoma. AJR Am J Roentgenol. 2001;176:399-406.
27. Munot K, Dall B, Achuthan R, Parkin G, Lane S, Horgan K. Role of magnetic resonance imaging in the diagnosis and single-stage surgical resection of invasive lobular carcinoma of the breast. Br J Surg. 2002;89:1296-1301.
28. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980;243:1635-1639.